Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

London, United Kingdom (PressExposure) July 28, 2011 -- GlobalData analysis shows that the global postmenopausal osteoporosis (PMO) therapeutics market stood at $4.2 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 3.5% to reach $5.0

billion in 2010. GlobalData forecasts that the global PMO therapeutics market will grow at a CAGR of 4.7% over the next seven years to reach $6.8 billion by 2017. This moderate growth is attributed to increase in awareness among females about PMO and the increase in the patient population. The patent

expiry of Actonel (risedronate sodium), Boniva (ibandronate), Reclast (zoledronic acid), Evista (raloxifene) and Protelos (strontium malonate) during 2012 to 2014 will act as the major barriers for the growth of PMO therapeutics market during the forecast period. The sales growth, will however, also be affected by Fosamax generics. The modest growth observed in the postmenopausal therapeutics market during 2010 to 2017 can also be attributed to the expected launch of pipeline products odanacatib (MK 0822) and NB S101 during the late forecast period, along with the increased prevalence of patients. The impending patent expiry of Boniva in 2012; Actonel and Reclast in 2013; and Evista in 2014 means patients will have access to treatment at much lower prices reflecting brand erosion of these drugs. The current competitive landscape mainly consists of bisphosphonates, selective estrogen receptor modulators (SERM), receptor activator of nuclear factor kappa-B ligand (RANK L) inhibitor drugs and hormone therapy with the bisphosphonates as the preferred drug for treatment. The treatment options available in the PMO therapeutics market include alendronate, Reclast, Actonel, Boniva, Evista, Prolia, Forteo (teriparatide), Miacalcin (calcitonin salmon), Prempro (estrogen) and Premarin (conjugated estrogens and medroxyprogesterone acetate).

GlobalData's research indicates that the PMO pipeline is strong with molecules in the various phases of

clinical development. Phase III has first-in-class products such as odanacatib, which possess a novel mechanism of action to combat PMO. NB S101 and PREOS are two other molecules in the late stages of

development. They are me-too products that belong to the dual action bone agent (DABA) class and parathyroid hormone class, respectively. The product extension molecule SMC 021 (oral calcitonin) is expected to increase patient adherence to therapy and improve the quality of life of PMO patients. To date, all four pipeline products have shown promising clinical study results to warrant their use in PMO

treatment. There is a significant unmet need as a number of PMO patients currently go untreated due to

adverse reactions and safety issues such as gastro-intestinal (GI) side effects. Many patients are unable

to comply with the strict dosage schedule. The significant unmet need can be addressed by drugs in future that have a convenient dosage pattern with better safety and efficacy results as compared to the currently available products in the market for the treatment of PMO.

For Sample Pages, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Post-Menopausal-Osteoporosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&CompanyID=pexpo

The PMO therapeutics market is distributed among a number of drugs: bisphosphonates, such as alendronate, Actonel, Boniva and Reclast; SERM such as Evista; RANKL inhibitors such as Prolia, and hormone therapy drugs, such as Prempro, Premarin, Activella, Miacalcin and Forteo. These agents although, do not completely satisfy the patients' needs, there remain a huge percentage of people looking for better treatment options in terms of safety, efficacy and dosage patterns for better compliance. Such patients do not have a choice but to continue with the presently available drugs, which closely meets their needs but not completely. Any drug that could successfully cater to the needs of this patient segment is expected to capture a major revenues share of the PMO therapeutics market.

GlobalData, the industry analysis specialist, has released its new report, "Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global postmenopausal osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global postmenopausal osteoporosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global postmenopausal osteoporosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Post-Menopausal-Osteoporosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&CompanyID=pexpo

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:

pressreleases@globaldata.com

North America: +1 646 395 5477

Europe: +44 207 753 4299

+44 1204 543 533

Asia Pacific: +91 40 6616 6782

About GlobalData

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries

Press Release Source: http://PressExposure.com/PR/GlobalData.html

Press Release Submitted On: July 28, 2011 at 2:22 am
This article has been viewed 40706 time(s).